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In Brief
Zheng et al. show a distinct type of large
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Identification of this cell type provides
insight into the complexity of the
metastatic tumor microenvironment. It
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origin of endothelial progenitor cells.
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The tumor microenvironment (TME) at the metasta-
tic site consists of multiple components with
considerable cellular heterogeneity. To test whether
endothelial cells (ECs) associated with lung metas-
tases express a distinct gene expression program
that promotes metastatic growth, we isolated
CD31+/CD45– cells from lung mammary cancer me-
tastases for RNA sequencing and found CD44
upregulation. Unexpectedly, the CD44+ subset did
not comprise authentic ECs nor were they bone-
marrow-derived CD45– endothelial progenitor cells.
Instead, they were a population of large platelets
that are distinct from regular small platelets. These
CD44+ large platelets were enriched in lung metas-
tases but not primary mammary tumors and
upregulated myeloid cell-regulating chemokines
indicative of potential regulation of metastasis via
indirect mechanisms. Identification of this cellular
player in the TME of metastasis suggests a role
for the recently identified lung-resident megakaryo-
cytes (MKs) and offers an unexplored route to
discover novel mechanisms and an opportunity for
therapeutic interventions.INTRODUCTION
Solid tumors are relatively successfully treated if restricted to the
primary site, but current therapeutics are inadequate in metasta-
tic diseases that cause the majority of patient deaths (Steeg,
2016). Anti-angiogenic therapies aim at inhibiting generation of
new blood vessels that support tumor growth and have shown
some effects in primary cancers, but the benefits for metastatic
breast cancer are limited (Potente et al., 2011). Blood vessels are
more than passive conduits for delivering nutrients to tumors orCell Repor
This is an open access article under the CC BY-Nfor cancer cell dissemination. Instead, they can positively regu-
late neighboring cells by expression of angiocrine factors (EC-
derived paracrine-acting factors) (Butler et al., 2010). However,
a comprehensive understanding of what angiocrine factors are
at the metastatic site and what biological processes they collec-
tively regulate is fundamentally lacking.
CD31 (also known as PECAM1) is a conventional EC marker
that is also expressed to varying degrees in platelets and certain
leukocyte subtypes (Lertkiatmongkol et al., 2016). It is also ex-
pressed by certain progenitor cells in the bone marrow (BM),
including endothelial progenitor cells (EPCs), which are believed
to be BM-resident non-hematopoietic progenitors for CD31+
circulating endothelial cells that can be incorporated into the
vessel network at the site of angiogenesis (Bertolini et al.,
2006; Gao et al., 2008; Patenaude et al., 2010). However,
EPCs have remained a controversial concept, as their contribu-
tion to vessels in tumors varies frommore than 50% to none, and
the exact cell of origin of the BM-derived CD31+ cells in tumors
has not been fully established (Medina et al., 2017; Patenaude
et al., 2010).
Another important component of the TME is the tumor-infil-
trating myeloid cells that promote tumor growth and metas-
tasis (Kitamura et al., 2015a; Powell and Huttenlocher, 2016).
Since inflammation can prime the endothelium to attract
myeloid cells to the site of infection, and inflammation and
cancer are intricately linked (Grivennikov et al., 2010), it is
thus plausible that disseminated cancer cells in secondary or-
gans may redirect the inflammatory response to recruit metas-
tasis-promoting myeloid cells indirectly via activation of the
endothelium.
Based on these data, we initially hypothesized that breast
cancer cells disseminated to the lung actively regulate non-
sprouting vessels that in turn provide signals to enhance meta-
static growth, either directly via activation of cancer cells or
indirectly via recruitment and regulation of myeloid cells. Unex-
pectedly, while attempting to address this hypothesis, we
uncovered a previously unrecognized population of large plate-
lets enriched specifically in lung metastases but not in primary
tumors.ts 29, 1747–1755, November 12, 2019 ª 2019 The Author(s). 1747
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Lung Metastases Induce an Increase of a CD44+ Subset of CD31+/CD45– Cells that Do Not Appear to Be Endothelial Cells
(A) Lungmetastases (mets.) induced by E0771-LG i.v. injection at day 11were dissected and processed to sortCD31+/CD45– cells and comparedwith those from
the normal lung without tumors.
(legend continued on next page)
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RESULTS
Gene Expression Profiling of CD31+/CD45– Cells from
Lung Metastases Reveals a Distinct CD44+ Population
First, we characterized the vessel phenotypes associated with
lung metastases using a spontaneous transgene-induced
mouse mammary tumor model of breast cancer (MMTV-PyMT,
Figures S1A–S1G) (Guy et al., 1992; Lin et al., 2003) and an
experimental metastasis model using tail vein injection of a met-
astatic mammary cancer cell line, E0771-LG (Kitamura et al.,
2015b) (Figures S1H–S1N). In both models, no sprouting angio-
genesis was observed in metastatic nodules that were visible to
naked eyes and were therefore macro-metastases by definition
(Figures S1F, S1G, S1I and S1K). Instead, these intratumor
vessels maintain their original anatomical structure found in the
alveoli of normal lungs (Figures S1F, S1G, and S1J). This con-
trasts with the sprouting angiogenesis in primary tumors, as
evident by dense microvessels with irregular morphology and
sprouting filopodia (Figures S1A–S1C). Not until day 13 in the
experimental model, when lesions had taken over much of the
space of the lung, did sprouting angiogenesis appear (Figures
S1L–S1N). These data suggest that sprouting angiogenesis is
not required for the initial and intermediate growth into macro-
metastases in the lung that is rich in capillary vessels.
To understand whether non-sprouting vessels in the lung pro-
mote metastatic growth via angiocrine factors, we isolated ECs
from lung metastases at day 11 post-intravenous (i.v.) injection
and compared with those of normal lung vessels using RNA
sequencing (RNA-seq) (Table S1). The cells were sorted by fluo-
rescence-activated cell sorting (FACS) based on their expres-
sion of the EC marker CD31 and negative expression for the
pan-leukocyte marker CD45 (Figure 1A). To further confirm the
EC identity, we used double-transgenic mice in which the fluo-
rescent protein tdTomato is expressed upon Cre-mediated
recombination in cells that express the EC marker VE-cadherin
(Cdh5) (Alva et al., 2006; Madisen et al., 2010). Analysis of
lung metastases from these Cdh5-Cre;Rosa26-loxp-stop-loxp-
tdTomato mice (Cdh5-tdT thereafter) showed that most of
CD31+/CD45– cells were positive for Cdh5-tdT (Figure 1B, Q1/
(Q1+Q4) = 86%). Unsupervised hierarchical clustering analysis
of the RNA-seq data completely segregated CD31+/CD45– cells
from normal lungs and dissected lung metastases into two
distinct clusters (Figure 1C), indicating a distinct gene expres-
sion program in metastases.
To understand how potential factors from this CD31+/CD45–
population may contribute to metastatic growth indirectly via
regulation of myeloid cells, we focused on two of the top ten(B) WT or Cdh5-tdT mice were i.v. injected with E0771-LG cells or untreated, an
(C) The gated cells from (A) were prepared for RNA sequencing. The gene expres
indicating individual samples.
(D) Independent qRT-PCR validation of Cd44. Ct, threshold cycle.
(E) Experimental metastases induced by E0771-LG i.v. injection were analyzed f
(F) Spontaneous lung metastases developed in 14.5-week-old PyMT mice were
(G–T) Normal lungs (G and K) or lungs bearing E0771-LG-Luc-ZsGreen (green)
confocal imaging, as presented in xy, xz, and yz views. Yellow arrows indicate C
occasions in which CD31+ ECs appear to express CD44. Orange and blue squa
(U) Quantification of CD31+ cells for CD44 positivity. Error bars represent SEM
See also Figures S1–S3.pathways enriched by the differentially expressed genes related
to leukocyte trafficking and function (Table S1, tab ‘‘Pathways’’).
CD44, a transmembrane glycoprotein involved in cell-cell inter-
action, cell adhesion, andmigration (Orian-Rousseau and Ponta,
2015), was identified by the RNA-seq as one of the significantly
upregulated genes enriched in these pathways and was also
confirmed by qRT-PCR analysis (Table S1, tab ‘‘Pathways’’; Fig-
ure 1D). This upregulation was also confirmed at the protein level
by FACS in both experimental and spontaneous models (Figures
1E and 1F).
The CD44+ Subset of CD31+/CD45– Cells in Lung
Metastases Does Not Appear to Be ECs
To analyze the spatial/anatomic information of CD31+/CD45–
CD44+ cells in relation to metastatic tumor cells, we transduced
E0771-LG cells with a lentivirus expressing luciferase-ZsGreen
(Luc-ZsG) to visualize tumor cells before i.v. injection (Figures
1G, 1L, and 1Q). As expected in the normal lung, ECs forming
pulmonary capillaries were CD44– (Figures 1G–1K). Surprisingly,
less than 3% CD31+ ECs appeared to be CD44+ in lung metas-
tases (Figures 1L–1U), in sharp contrast to the 69% observed by
flow cytometry (Figure 1E). Similar findings were observed also
for the spontaneous metastasis model (Figures 1F and S2).
The apparent discrepancy between flow-cytometry-based and
histology-based evaluation was not unique to the Cd44 gene
but was also for a number of other tested genes, such as
Thbd, which showed downregulation in flow cytometry but not
in histology (Figures S3A and S3B). Interestingly, most of the
CD44+ subset of CD31+/CD45– cells were THBD– (Figure S3A),
suggesting that the CD44+ subset in metastases represents a
distinct cellular population. Indeed, when backgated to the
live-cell gate, the CD44+ appeared to cluster differently from
the CD44– subset, with slightly less CD31 and slightly more
CD45 staining intensities (Figure S4A).
CD31+/CD45–/CD44+ Cells Associated with Lung
Metastases Originate from the CD45+ Hematopoietic
Lineage in the BM
Next, we set out to determine whether the distinct
CD31intermediate/CD45dim/CD44+ (CD31int/CD45dim/CD44+) popu-
lation that was also labeled by the Cdh5-tdT reporter (Figure 1B)
represents tumor EC heterogeneity (Dudley, 2012) or a yet-un-
identified population in the TME. First, we examined two addi-
tional parameters commonly used for determining EC identity,
VE-cadherin antibody staining, and tomato lectin binding (Baluk
and McDonald, 2008; Gao et al., 2008). VE-cadherin antibody
staining in flow cytometry may underestimate the true numberd the lungs were analyzed after 11 days.
sion data were analyzed using unsupervised hierarchical clustering, with bars
or CD44 expression in the CD31+/CD45– population.
similarly analyzed.
metastases (L–T) were sectioned and stained for CD31, CD44, and DAPI for
D31+ ECs that do not express CD44, and yellow arrowheads indicate the rare
res in (K) and (P) are zoomed in panels as indicated. Scale bars, 20 mm.
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Figure 2. CD31+/CD45–/CD44+ Cells Enriched
in Lung Metastases Originate from the CD45+
Hematopoietic Lineage in the BM
(A–C) Total BM cells from Actb-EGFP donor mice
were transplanted into WT recipient mice. After
5 weeks, E0771-LG cells were injected i.v., and the
normal lungs without tumor cell injection or lung
metastases were analyzed.
(D–G) The CD45/TER119 and CD45+/TER119
populations were sorted from the total BM cells of
Actb-EGFP donor mice and were combined with or
without WT supporting cells as indicated for trans-
plantation of WT recipient mice. E0771-LG cells
were injected i.v. 5 weeks after transplantation.
(H) Analysis of group 3 in (E) for CD44 and EGFP.of positive cells (66.3% of CD31+/CD45–, Figure S4B), possibly
due to tissue digestion needed for single-cell preparation. Never-
theless, CD31int/CD45dim/CD44+ cells in lungmetastases still ex-
pressed a significant level of VE-cadherin, in contrast to the 1.9%
of CD45+ cells as a negative control (Figure S4B, Q1/(Q1+Q2)).
92% of CD31int/CD45dim/CD44+ cells in lung metastases were
labeled with lectin after i.v. injection (Figure S4C, Q1/(Q1+Q2)).
Cdh5-tdT reporter mice also confirmed that most of CD31int/
CD45dim/CD44+ cells in lung metastases were positive for the re-
porter (Figure S4D, Q1/(Q1+Q2)). Thus, flow cytometric analysis
with conventional EC markers cannot exclude their EC identity.
We then studied the possible involvement of CD31+ cells that
are not ECs. We excluded the possibility of tumor cell contami-
nation due to vasculogenic mimicry, by which tumor cells ex-
press CD31 and become part of the endothelium (Seftor et al.,
2012), as ZsGreen+ tumor cells were negative for CD31 staining
in both histology and flow cytometry (Figures 1L–1T; Figure S4E).
They are unlikely to be CD31-expressing monocytic cells either
(Kim et al., 2009; Urbich et al., 2003), since, in addition to the1750 Cell Reports 29, 1747–1755, November 12, 2019relative absence of the pan-leukocyte
marker CD45, the myeloid cell marker
CD11B expressed by monocytic cells was
also negative (Figure S4F).
BM-derived EPCs have been suggested
as a source for CD31+ cells in tumors (Ber-
tolini et al., 2006; Patenaude et al., 2010).
We reasoned that, if the CD44+ subset of
CD31+/CD45– cells originates from EPCs
in the BM, they would be labeled in a BM
transplantation (BMT) experiment using a
colored reporter. Thus, we transplanted to-
tal BM cells from Actb-EGFP mice (EGFP
expression driven by the beta-actin pro-
moter) (Okabe et al., 1997) into wild-type
(WT) recipient mice so that BM-derived
cells but not pre-existing ECs in lung ves-
sels would be labeled with EGFP. Similar
to a previous finding (Gao et al., 2008),
the percentage of BM-derived cells in the
CD31+/CD45– population was significantly
increased in lung metastases compared
to that in normal lungs (Figures 2A and2B). Importantly, the majority of CD44+ cells that increased in
the CD31+/CD45– population in lung metastases were EGFP+
(Figure 2C), indicating that BM is the source of these cells. Puta-
tive EPCs has been postulated to be CD45– non-hematopoietic
progenitors in the BM (Gao et al., 2008; Patenaude et al.,
2010). However, formal experimental proof for this hypothesis
is lacking. To determine whether EPCs by this definition is the
cell of origin of our observed CD31int/CD45dim/CD44+ cells in
lung metastases, we FACS-sorted non-hematopoietic cells
(CD45–/TER119–) and hematopoietic cells not including erythro-
cytes (CD45+/TER119–) from the BM and compared their ability
to generate CD31int/CD45dim/EGFP+ cells in lung metastases
after BMT (Figures 2D and 2E). The result showed that only pro-
genitors of the hematopoietic lineage (CD45+/TER119–) gave rise
to CD31+/CD45– cells (of which most were CD44+) in a dose-
dependent manner, and, when given at a similar dose, CD45+
engraftment was similarly efficient as total BM cells, in contrast
to the undetectable level engrafted by non-hematopoietic
CD45– cells (Figures 2F and 2G). In addition, the majority of
CD31+/CD45dim/CD44+ cells originated fromCD45+ BM progen-
itors (Figure 2H). Thus, it can be concluded that it is CD45+
hematopoietic progenitor cells in the BM that give rise to metas-
tasis-infiltrating CD31int cells that are CD45dim.CD31int/CD45dim/CD44+ Cells Accumulated in Lung
Metastases Are Large Platelets
Next, we studied how CD45+ hematopoietic progenitors gener-
ated CD31int/CD44+ cells in lung metastases that were CD45dim.
We ruled out that they are CD45– erythrocytes in metastases, as
they were negative for the lineage marker TER119 (Figure S4G).
Platelets also express CD31 and are another subset of hemato-
poietic cells without CD45 expression (Newman and Newman,
2003). Indeed, we found that CD31int/CD45dim/CD44+ cells in
lung metastases were predominantly positive for the platelet
marker CD41 (Figures 3A and 3B). Nuclear staining by Hoechst
(Hst) confirmed that these cells did not have nuclear DNA (Fig-
ures 3C and 3D). Similar results were observed in the sponta-
neous model (Figure 3E). Next, we FACS-sorted these cells
and plated them on a glass slide for fluorescent microscopy.
As expected, CD31+/CD45– from the normal lung were positive
for CD31 and nuclear staining, while the CD31–/CD45+ leuko-
cytes, despite their nuclear staining by Hst, were CD31– (Fig-
ure 3F, left two columns). In comparison, while the CD31int/
CD45dim/CD44–/Hst+ cells sorted from metastases appeared
to represent authentic ECs due to positive staining for both
CD31 and Hst, the CD44+/Hst– subset did not show nuclear
staining despite their CD31 staining (Figure 3F, right two col-
umn). These cells therefore appeared to be platelets.
To further confirm the platelet identity, we used a reporter
mouse in which tdTomato expression is controlled by the MK/
platelet lineage marker Pf4, Pf4-tdT (Madisen et al., 2010; Tiedt
et al., 2007). Whereas mice without tumor cell injection showed
little PF4-tdT signal in CD31+/CD45dim cells in the lung, a signif-
icant fraction of the CD31+/CD45dim cells in lung metastases
highly expressed PF4-tdT (Figures 3G and 3H). Importantly,
these PF4-tdT+ cells were predominantly CD44+/CD41+/Hst–
(Figure 3H), which reinforces the platelet identity of these cells.Lung Metastases but Not Primary Tumors Induce
Accumulation of Chemokine-Expressing CD31int/
CD45dim/CD44+ Large Platelets
To examine whether CD31int/CD45dim/CD44+ platelets exhibit
any distinct features compared to regular platelets, we
compared their sizes and CD44 expression and found that
CD31int/CD45dim/CD44+ were larger and that only these cells ex-
press CD44 (Figure 4A). Next, we tested whether CD31int/
CD45dim/CD44+ large platelets exist in the blood circulation
before they were recruited to lung metastases or even in the
blood of normal mice. Indeed, we found CD31int/CD45dim cells
in the normal blood as described also by others (Strijbos et al.,
2007; Wong et al., 2012) and that these cells were CD44+/
CD41+/Hst– (Figure 4B, P1). However, the number of CD31int/
CD45dim/CD44+ cells did not increase in the blood of metas-
tasis-bearing mice (Figure 4C), despite their marked increase
in lung metastases (Figure 1E), suggesting local production in
the lung.Subsequently, we wanted to understand whether CD31int/
CD45dim/CD44+ large platelets enriched in lung metastases ex-
press chemokines that may regulate recruitment and function
of myeloid cells and thus metastatic growth indirectly. qRT-
PCR analysis of these cells strikingly revealed that only the
CD31int/CD45dim/CD44+ large platelets accumulated in lungme-
tastases highly expressed a number of chemokines identified in
the RNA-seq, such asCxcl2,Cxcl10,Cxcl1,Cxcl3, andCcl2 data
(Table S1, tabs ‘‘Pathways,’’ ‘‘Agranulocyte Adhesion and Dia-
pedesis,’’ and ‘‘Leukocyte Extravasation Signaling’’; Figure 4D).
Neither those in the blood of normal mice or metastasis-bearing
mice showed detectable levels (Figure 4D). This observation
again indicates a local effect in the lung, which prompted us
to examine the primary mammary tumors. Notably, very few
CD31int/CD45dim/CD44+ large platelets were detected in
MMTV-PyMT primary tumors (Figure 4E), in sharp contrast to
the lung metastases in this model (Figure 1F). In comparison,
regular small platelets did not show such a lung-preferential
enrichment, as they were present in a similar level in primary
tumors as in normal mammary fat pads (Figure S5). A recent
important finding showed that lung megakaryocytes (MKs) in
the BM can egress from the BM and reside in the lung and
contribute to platelet production (Lefranc¸ais et al., 2017).
Consistent with these data, we observed in lung metastases
Pf4-tdT+ MKs (Figure 4F) that may represent the source of the
chemokine-expressing large platelets enriched only in lung me-
tastases. Interestingly, Pf4-tdT+ MKs in mice that received Pf4-
tdT BMT increased in lung metastases (Figure 4F), suggesting
that lung metastases may induce MK migration from the BM to
the lung or in situ proliferation.
DISCUSSION
We initially set out to test whether cancer cells colonizing the
lung induce a distinct expression program in associated ECs.
To our surprise, we found in this study a previously unrecognized
yet distinct population of CD31int/CD45dim/CD44+large platelets
restricted to lung metastases.
Our unexpected findings have helped to clarify the controver-
sial concept of EPCs. It was postulated but not experimentally
proved that EPCs are a population of CD45– non-hematopoietic
progenitors in the BM that are able to generate BM-derived
CD31+/CD45– cells in tumors, including lung metastases (Gao
et al., 2008; Patenaude et al., 2010). However, our lineage tracing
experiments that compared CD45+ and CD45– BM cells for this
progenitor ability has provided strong evidence that BM-derived
CD31+/CD45– cells, at least in lung metastases, originate from
CD45+ hematopoietic progenitors. This finding argues against
the in vivo existence of a unique population of EPCs located in
the BM that are non-hematopoietic. It should be noted that we
do not exclude differentiation into ECs fromBM-derived hemato-
poietic progenitor cells (Moschetta et al., 2014; Patenaude et al.,
2010) or from vessel-wall-derived progenitors (Ingram et al.,
2005; Fang et al., 2012; Wakabayashi et al., 2018). However,
this is not the conventional definition of EPCs that emphasizes
the BM origin and the non-hematopoietic identity.
Platelets are released from MKs with an intermediate stage of
proplatelets (Patel et al., 2005). The CD31int/CD45dim/CD44+Cell Reports 29, 1747–1755, November 12, 2019 1751
Figure 3. CD31int/CD45dim/CD44+ Cells Enriched in Lung Metastases Are CD41+/Hoechst–/Pf4+ Platelets
(A–D) Lung metastases induced by E0771-LG i.v. injection were analyzed after 11 days for CD41 expression (A and B) or Hoechst (Hst) staining (C and D).
(E) Lung metastases were dissected from 14.5-week-old PyMT mice for similar analyses.
(F) The indicated cell populations from the experimental metastasis model were sorted and fixed on a glass slide for imaging. Arrows indicate CD31+/Hst+ ECs;
arrowheads indicate CD31+/Hst– platelets. Scale bars, 25 mm.
(G) WT mice that received Pf4-tdT BMT were either untreated or i.v. injected with E0771-LG. After 11 days, the lungs and lung metastases were analyzed.
(H) Quantification of (G). All error bars represent mean ± SEM.
See also Figure S4.large platelets identified in our study may represent this poorly
understood intermediate form. Recently Lefrancais et al. showed
that MKs commonly found in the BM canmigrate to and reside in1752 Cell Reports 29, 1747–1755, November 12, 2019the lung, where they contribute up to 50% of the total platelet
production (Lefranc¸ais et al., 2017). These lung-resident MKs
are likely the source of the CD31int/CD45dim/CD44+ large
Figure 4. LungMetastases But Not Primary Tumors Induce Accumulation of Chemokine-Expressing CD31int/CD45dim/CD44+ Large Platelets
(A and B) Comparison of CD31int/CD45dim/CD44+ large platelets and regular small platelets in the lung (A) and blood (B). Note the same values of 104 (red text and
arrows) on different scales of forward scatter (FSC).
(C) Quantification of CD31int/CD45dim/CD44+ large platelets in the blood of normal and metastasis-bearing mice.
(D) CD31int/CD45dim/CD44+ large platelets from the normal blood, the blood of metastasis-bearing mice, and dissected lung metastases were sorted for qRT-
PCR analysis.
(legend continued on next page)
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platelets that are enriched and activated only in lungmetastases.
Future work such as intravital imaging is required to provide
direct evidence of this assertion and to obtain the spatial-tempo-
ral information of themultiple cell types inmetastases. Neverthe-
less, our findings have extended the significance of the lung-
resident population of MKs by showing that they represent a
distinct player that releases chemokine-expressing large plate-
lets to metastatic cancer cells in the lung.
The exact function of CD31int/CD45dim/CD44+ large platelets
requires further study. They may use similar mechanisms as reg-
ular small platelets to promote cancer cell extravasation and
metastatic growth (Haemmerle et al., 2018), or they may also
have distinct roles. For example, only the CD31int/CD45dim large
platelets but not regular small ones expressed CD44. Since
CD44 binds to HA, and HA deposition by tumor and stromal cells
is enhanced upon their interaction (Kimata et al., 1983; Knudson
et al., 1984), CD31int/CD45dim/CD44+ large plateletsmay use this
adhesion mechanism to accumulate in metastases. Elucidation
of the specific activities of this population will require advances
that allow perturbation of only these atypical platelets but not
the regular ones. Unfortunately, unique tools to study this cell
population do not exist. Despite the limitations, our observation
that lung metastases induced upregulation of chemokines in
CD31int/CD45dim/CD44+ large platelets has shed important
mechanistic insights, since many of these chemokines have
been shown in a variety of studies to regulate the recruitment
and activity of monocytes, macrophages, and neutrophils to pro-
mote extravasation, seeding, and colonization of disseminated
tumor cells (Coffelt et al., 2016; Kitamura et al., 2015a). Addi-
tional future work is needed to determine the amount and func-
tional effects of these chemokines as compared to those from
other stromal cells in the TME including regular platelets.
Identification of this platelet population has advanced our un-
derstanding of the heterogeneity and complexion of the TME in
metastases. Our study suggests that metastatic cancer cells
may trigger organ-specific responses. Elucidation of thesemech-
anisms may offer opportunities for design of novel therapeutics.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
All procedures involving mice were conducted in accordance with National Institutes of Health regulations concerning the use and
care of experimental animals and were approved by the Albert Einstein College of Medicine Animal Use Committee. MMTV-PyMT
mice were provided by W.J. Muller (McMaster University, Hamilton, Ontario, Canada) (Guy et al., 1992) and bred in house in the
FVB background. Cdh5-Cre (Stock number 006137), Rosa26-LSL-tdTomato (Stock number 007914), Actb-EGFP (Stock number
006567), Pf4-Cre (Stock number 008535) and C57BL6/J WT mice were purchased from the Jackson Laboratory. Only female
mice were used in breast cancer models.
Cell lines
E0771-LG (Kitamura et al., 2015b) and 293T cells were cultured in DMEM supplemented with 10% v/v fetal bovine serum and peni-
cillin/streptomycin.
METHOD DETAILS
Lung metastasis assays
Spontaneous metastases in the lung developed in MMTV-PyMT mice were collected when mice were 14-15 weeks old. For exper-
imental metastasis assays, 1 3 106 E0771-LG were injected intravenously through the tail vein of syngenic C57BL6/J female mice
(6-8 wk old unless otherwise specified). For in vivo analysis of lectin binding, 50mg biotinylated tomato-lectin (Vector Lab, B-1175)
was injected into the retro-orbital sinus and was analyzed 10 min after injection by staining with streptavidin-conjugated BUV395
(BD Biosciences 564176).
Viral production and transduction of tumor cells
293T cells were transfected with pHIV-Luc-ZsGreen (gift fromDr. BryanWelm, Addgene #39196), pMD2.G (gift fromDr. Didier Trono,
Addgene #12259) and pxPAX2 (gift from Dr. Didier Trono, Addgene #12260) at 4:3:1 in mg using Lipofectamien 2000 (Invitrogen,
#11668-019) according to the manufacturer’s manual. Medium was replaced 4-6 hours (h) after transfection with DMEM containingCell Reports 29, 1747–1755.e1–e4, November 12, 2019 e2
2% v/v FBS. Viral supernatants were collected 48 and 72 h after transfection, pooled, cleared with a 0.2 mm filter and used for trans-
duction. Target cells were seeded at about 50% confluency, incubated with the viral supernatant and 10 mg/mL polybrene (Santa
Cruz, sc-134220) and centrifuged at 1000 G for 30 min at room temperature (RT). The virus was removed and the cells were then
cultured for 3 days before FACS sorting for ZsGreen+ cells.
Flow cytometry and cell sorting
Lungs were perfused with PBS through the right ventricle, dissected and minced. Lung metastases (< 1 mm in diameter) were
dissected using a dissection microscope and pooled from 2-4 mice. The tissues were then digested with an enzyme mix of Liberase
DL (Sigma-Aldrich 5466202001, 0.52 U/mL), TL (Sigma-Aldrich 5401020001, 0.26 U/mL) and DNase I (Sigma-Aldrich DN25,
150 mg/mL) diluted in basal DMEM medium with rotation for 30 min at 37C and filtered (70-mm membrane). For cells sorted for
qRT-PCR, transcription inhibitors alpha-amanitin (Sigma-Aldrich A2263, 5 mg/mL) and actinomycin D (Sigma-Aldrich A1410,
1 mg/mL) were also added in the digestion buffer. Mouse peripheral blood was collected from the major abdominal vessels (inferior
vena cava) with a syringe containing 150 mL ACD buffer [85 mM trisodium citrate, 71 mM citric acid, and 111 mM dextrose (pH 4.5)]
(Gil-Bernabe´ et al., 2012). Red blood cells were removed by incubation with the RBC Lysis Buffer (Biolegend, 420301) for 5min on ice
(once for tissues and twice for blood). Before antibody labeling, cells were blocked with anti-mouse CD16/CD32 antibody (BD Bio-
sciences 553141) for 10 min on ice. Flow cytometry was performed with a LSRII cytometer (BD Biosciences) and the data were
analyzed using Flowjo software (TreeStar). FACSAria II (BD Biosciences) and Moflo Astrios (Beckman Coulter) were used for cell
sorting.
Gating of single cells using FSC-A/H and SSC-A/W and exclusion of dead cells with DAPI, Zombie Yellow (Biolegend 423103) or
Zombie Green (Biolegend 423111) staining were performed routinely during analysis. For Hoechst staining, cells were incubated with
5 mg/mL Hoechst 33342 (BD Biosciences, 561908) for 10 min at 37C before antibody staining. For visualization of sorted cells on a
glass slide for microscopy, the sorted cells were pelleted, resuspended in 10 mL PBS, pipetted to a glass slide enclosed by a hydro-
phobic pen (Vector Laboratories, H-4000) and air-dried in a laminar hood. The cells were then fixed with 4% w/v paraformaldehyde
(PFA) for 10 min at room temperature and mounted with VECTASHIELD Mounting Medium (Vector Laboratories, H-1000). For quan-
tification of cell numbers, CountBrignt abosolute counting beads (ThermoFisher Scientific, Cat# C36950) were used according to the
manual.
BMT
Total BM cells were extracted from femurs, tibiae and the spine by grinding in a mortar. For BMT involving cell sorting, an additional
step was performed to purify low-density mononuclear cells by using density gradient centrifugation with Histopaque 1083 (Sigma-
Aldrich 1083-1) before antibody staining. Female recipient mice of 4-6 weeks old were irradiated with 10 Gy gamma rays (split into 2
doses with a 4-h interval) the day before iv injection of 5-103 106 BM cells unless otherwise specified. Transplanted mice were used
for experiments after 4-5 weeks.
RNA isolation, qRT-PCR and RNA sequencing
Cells were sorted directly into the Extraction Buffer of the Picopure RNA Isolation kit (Arcturus KIT0202). RNA sequencing of mouse
total RNA was performed at Beijing Genomic Institute, using the Ovation RNA-Seq System V2 kit for library construction, pair-end
100 bp and Hiseq 4000, which generated 60-80M reads per sample. The reads were aligned to the mouse reference genome
(GRCm38/mm10) using Tophat (v2.0.13) (Kim et al., 2013). Uniquely mapped reads were counted for each gene using htseq-count
in the HTSeq package (v0.6.1) with gene models from UCSC RefGene (Anders et al., 2015). FPKM values were generated using cuf-
flinks v2.2.1 (Trapnell et al., 2013). Lowly expressed genes (mean FPKM values < 1 in both groups under comparison) were excluded
from differential expression analysis. DESeq2 was used to identify differentially expressed genes (Love et al., 2014), of which fulfilling
the following criteria were used for enrichment of Canonical Pathways in the Ingenuity Pathway Analysis (QIAGEN): log2 (fold change)
> 1.5; false discovery rate (FDR) < 0.03; for upregulated genes, mean FPKMs of lung metastases > 20; for downregulated genes,
mean FPKMs of normal lungs > 20.
For qRT-PCR, the isolated RNAs were reverse transcribed and amplified using QuantiTect Whole Transcriptome (QIAGEN
207043) before qPCR. Gene expression was normalized to beta-actin. Relative expression is calculated using the formula –DDCt,
where Ct stands for threshold cycles. Undetectable expressions were assigned a relative Ct value of 20 with respect to the Ct
of beta-actin. The following Taqman gene expression assays (ThermoFisher Scientific) were used: Actb (Mm02619580_g1), Ccl2
(Mm00441242_m1), Cd44 (Mm01277161_m1), Cxcl1 (Mm04207460_m1), Cxcl2 (Mm00436450_m1), Cxcl3 (Mm01701838_m1),
and Cxcl10 (Mm00445235_m1).
Immunofluorescent staining and microscopy
Mouse lungswere processed for frozen sectioning using amethodmodified froma previous study (Favre et al., 2003). Briefly, the lung
were perfused with 1% w/v PFA through the right ventricle, and then 2% agarose diluted in PBS were infused into the lung via the
trachea to expand alveoli. After dissection with the associated trachea, the lungs were kept in the inflated form in a histology cassette
for further immersion fixation in 4% w/v PFA for 1 h at +4C, and were then washed with PBS and incubated with 25% w/v sucrose
before frozen embedding in the OCT Compound (Fisher HealthCare 4585). Twenty-mm frozen sections were cut, air-dried for 1 h,e3 Cell Reports 29, 1747–1755.e1–e4, November 12, 2019
permeabilized and blocked using Donkey Immunomix (PBS containing 5% v/v normal donkey serum, 0.2% w/v bovine serum albu-
min, 0.3% Triton-X and 0.05%w/v sodium azide) for 1 h, stained overnight at +4Cwith primary antibodies, washed and then stained
with secondary antibodies for 1-1.5 h at RT. Sections were thenmounted with VECTASHILDMountingMedium (Vector Laboratories,
#H-1200). Samples were imaged using the Leica SP8 confocal microscope (Leica). For confocal images, 3D projections and orthog-
onal viewswere digitally reconstructed fromZ stacks using ImageJ. Brightness and contrast of the imageswere adjusted uniformly to
entire images using Adobe Photoshop where appropriate. Quantification of the percentage of CD44+ cells out of CD31+ ECs was
performed on confocal images. A cell was identified as double positive only when they colocalized to the same cell from all xy, xz
and yz views. A total of approximately 50 CD31+ cells per mouse were analyzed.
QUANTIFICATION AND STATISTICAL ANALYSIS
The majority of experiments were repeated two or more times as indicated in the figure legends. A few experiments were performed
once, with NR 3mice per group. Student’s t test (2 groups) or one-way ANOVA (> 2 groups) were used to comparemeans. Two-way
ANOVA was used when data frommultiple experiments were pooled. When variances are unequal among different groups as deter-
mined by F test, logarithmic transformation to base 10 is used to compute the statistics. Data are presented asmean ± standard error
of mean (SEM). Holm-Sidak test was used as a post hoc analysis when more than two groups were compared. Statistical analyses
were carried out with Graphpad Prism (version 7), and the significance is indicated in the figures as follows: p < 0.05 (*), p < 0.01 (**),
p < 0.001 (***), p < 0.0001 (****), and not significant (N.S.). For RNA-seq analysis, multiple hypothesis testing was adjusted using the
Benjamini and Hochberg false-discovery-rate method.
Sample sizes for quantifications are as follows. Figures 1D and 1E: N = 4mice for normal lungs and 8mice pooled into 4 samples for
metastases. Figure 1F: N = 4 samples pooled from 4 independent experiments, each pooled from 5-7mice. N = 8mice forWT in total.
Figures 2B and 2C: N = 4 mice for normal lungs and 8 mice pooled into 4 samples for lung metastases. Figure 2H: N = 2-4 mice per
group. Figures 3A and 3B, N = 6 mice for normal, 12 mice pooled into 5 samples for metastases, and 2 independent experiments are
pooled. Figures 4C and 4D: N = 4 mice for normal lungs and 8 mice pooled into 4 samples for metastases. Figure 3E: N = 4 samples
from 4 independent experiments, each pooled from 5-7 mice. Figure 3H: N = 7 mice pooled from 2 independent experiments. Fig-
ure 4C: N = 5-11 samples pooled from 10-22mice from 3 independent experiments in total. Figure 4D: N = 2-6 pooled from 8-21mice
from 3 independent experiments in total. Figure 4E: N = 4-5mice in total from two independent experiments. Figure 4F: N = 4-5mice.
All bar graphs represent means ± SEM. Lines in scatterplots indicate means.
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